A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521416-19-00

Enrollment

Registered

2026-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence of Clostridioides difficile Infection

Brief summary

First occurrence of recurrent C. difficile infection

Detailed description

Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection)

Interventions

DRUGPlacebo for AZD5148

DRUGAZD5148

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
First occurrence of recurrent C. difficile infection	—

Secondary

Measure	Time frame
Sustained clinical cure (ie, achievement of initial clinical cure + no recurrent C. difficile infection)	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 18, 2026